METAP2 and cancer: Interestingly, the enzyme MetAP2 is the biological target of the very well-known antiangiogenic compounds fumagillin and ovalicin [21,22], and their selectivities against MetAP2 is a key factor that is being explored, not only for the treatment of cancer but also for the development of antiobesity agents [23].